Eventide Healthcare Life Fund Investor Sentiment

ETNHX Fund  USD 35.88  0.06  0.17%   
Slightly above 62% of Eventide Healthcare's investor base is looking to short. The analysis of overall sentiment of trading Eventide Healthcare Life mutual fund suggests that many investors are alarmed at this time. Eventide Healthcare's investing sentiment can be driven by a variety of factors including economic data, Eventide Healthcare's earnings reports, geopolitical events, and overall market trends.
  
over a year ago at www.macroaxis.com         
Payment of 635 shares by Stephen Webster of Spark Therapeutics subject to Rule 16b-3
Macroaxis News
over a year ago at news.google.com         
Rain Oncology Multiple Data Catalysts In 2023 For This Precision ... - Seeking Alpha
Google News at Macroaxis
over three months ago at seekingalpha.com         
Tectonic, AVROBIO complete merger, announce 130.7M private placement
seekingalpha News
over three months ago at news.google.com         
Gabelli Funds LLC Invests 467000 in AVROBIO, Inc. - Defense World
Google News at Macroaxis
over six months ago at news.google.com         
AVROBIO, Inc. Short Interest Up 11.3 percent in May - MarketBeat
Google News at Macroaxis
over six months ago at investing.com         
Avrobio executive buys shares worth over 970k
Investing News at Macroaxis
over six months ago at investorplace.com         
AVRO Stock Earnings Avrobio Beats EPS for Q1 2024
sbwire news
over six months ago at news.google.com         
AVROBIO Options Chain Prices 2024 - MarketBeat
Google News at Macroaxis
over six months ago at news.google.com         
AVROBIO Posts Quarterly Earnings Results - MarketBeat
Google News at Macroaxis
over six months ago at thelincolnianonline.com         
AVROBIO, Inc. Sees Significant Drop in Short Interest
news
over six months ago at benzinga.com         
SHAREHOLDER UPDATE Halper Sadeh LLC Investigates AXNX, KAMN, JNPR, AVRO
benzinga news
over six months ago at news.google.com         
AVROBIO INVESTOR ALERT by the Former Attorney General of Louisiana Kahn Swick Foti, LLC Investigates...
Google News at Macroaxis
few days ago at gurufocus.com         
Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference
Gurufocus Stories at Macroaxis
over a week ago at news.google.com         
Supernus Pharmaceuticals Reaches 80-Plus Relative Strength Rating Benchmark - Inkl
Google News at Macroaxis
over two weeks ago at gurufocus.com         
ARMISTICE CAPITAL, LLC Acquires Significant Stake in Rockwell Medical Inc
Gurufocus Stories at Macroaxis
over two weeks ago at gurufocus.com         
ARMISTICE CAPITAL, LLC Acquires New Stake in Protagenic Therapeutics Inc
Gurufocus Stories at Macroaxis
over two weeks ago at gurufocus.com         
Supernus Pharmaceuticals Inc Shares Gap Down to 36.57 on Nov 14
Gurufocus Stories at Macroaxis
over two weeks ago at news.google.com         
Supernus Pharmaceuticals Recently Launched Qelbree Is Powering Growth - Seeking Alpha
Google News at Macroaxis
over three weeks ago at investing.com         
Supernus Pharmaceuticals director sells shares worth 520,480
Investing News at Macroaxis
over three weeks ago at finance.yahoo.com         
Supernus Pharmaceuticals Third Quarter 2024 Earnings Beats Expectations
Yahoo News
over three weeks ago at finance.yahoo.com         
Supernus Reports Q3 Earnings What Key Metrics Have to Say
Yahoo News
over three weeks ago at finance.yahoo.com         
Supernus Pharmaceuticals Inc Q3 2024 Earnings Call Highlights Strong Revenue Growth and ...
Yahoo News
a minute ago at thelincolnianonline.com         
AbbVie Inc. Shares Sold by Janney Montgomery Scott LLC
news
2 days ago at insidermonkey.com         
Why AbbVie Inc. Is One of the Most Profitable Pharmaceutical Stocks Right Now?
insidermonkey News
3 days ago at finance.yahoo.com         
Pharma Stock Roundup RHHBY to Buy PSTX, MRK, AZN See Pipeline Success
Yahoo News
few days ago at thelincolnianonline.com         
Financial Counselors Inc. Acquires 4,500 Shares of AbbVie Inc.
news
few days ago at finance.yahoo.com         
Head and Neck Cancer Therapeutics Global Market Overview 2024-2030 Advancements in Immunotherapy and...
Yahoo News
few days ago at businesswire.com         
AbbVie Digital Transformation Strategy Report 2024 - Accelerators, Incubators and Other Innovation P...
businesswire News
few days ago at thelincolnianonline.com         
AbbVie Inc. Shares Sold by The Manufacturers Life Insurance Company
news
few days ago at cnbc.com         
This 13 billion ETF that tracks high-momentum stocks just got a makeover. Heres what changed
cnbc News
six days ago at gurufocus.com         
AbbVie to Present at Citis 2024 Global Healthcare Conference
Gurufocus Stories at Macroaxis
six days ago at zacks.com         
AbbVie Stock Rises After Leerink Partners Upgrades Its Rating
zacks News
a day ago at simplywall.st         
Veracyte, Inc. Surges 25 percent Yet Its Low PS Is No Reason For Excitement
Simply Wall St News at Macroaxis
3 days ago at gurufocus.com         
Insider Sell Alert Jonathan Wygant Sells Shares of Veracyte Inc
Gurufocus Stories at Macroaxis
over a week ago at investing.com         
Veracyte director Karin Eastham sells shares worth 564,768
Investing News at Macroaxis
over a week ago at thelincolnianonline.com         
Cornercap Investment Counsel Inc. Purchases New Stake in Veracyte, Inc.
news
over two weeks ago at thelincolnianonline.com         
Veracyte, Inc. Shares Sold by Sumitomo Mitsui Trust Group Inc.
news
over two weeks ago at gurufocus.com         
Artisan Partners Limited Partnership Bolsters Stake in Veracyte Inc
Gurufocus Stories at Macroaxis
over two weeks ago at simplywall.st         
Disposition of 15000 shares by Epstein Robert S of Veracyte at 8.04 subject to Rule 16b-3
Simply Wall St News at Macroaxis
over two weeks ago at thelincolnianonline.com         
Veracyte Releases Quarterly Earnings Results, Beats Estimates By 0.16 EPS
news
over three weeks ago at finance.yahoo.com         
Veracyte Third Quarter 2024 Earnings Beats Expectations
Yahoo News
over three weeks ago at investing.com         
Veracyte stock target lifted, sustains buy rating on strong Q3 results
Investing News at Macroaxis
3 days ago at prnewswire.com         
BLUE LOCK CEMENTS ITSELF AS AN INTERNATIONAL HIT AS EPISODE NAGI EARNS 23.3 MILLION AT THE GLOBAL BO...
prnewswire News
few days ago at seekingalpha.com         
FDA investigating safety risks of bluebirds Skysona
seekingalpha News
over a week ago at prnewswire.com         
BLUE CROSS BLUE SHIELD OF MASSACHUSETTS ANNOUNCES NEW GRANTS AS PART OF ONGOING WORK TO ADDRESS HEAL...
prnewswire News
over two weeks ago at investing.com         
JPMorgan skeptical of bluebird bio stock recovery, downgrades to underweight
Investing News at Macroaxis
over two weeks ago at thelincolnianonline.com         
bluebird bio Downgraded by JPMorgan Chase Co. to Underweight
news
over two weeks ago at businesswire.com         
bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidanc...
businesswire News
over two weeks ago at prnewswire.com         
BLUE CROSS BLUE SHIELD OF MASSACHUSETTS CONTINUES TO EXPAND ACCESS TO WOMENS HEALTH SERVICES AND FAM...
prnewswire News
over two weeks ago at prnewswire.com         
BLUE CROSS BLUE SHIELD OF MASSACHUSETTS LAUNCHES REFRESHED HEALTH EQUITY BUSINESS ACCELERATOR WITH M...
prnewswire News
over three weeks ago at finance.yahoo.com         
After Plunging -22.76 percent in 4 Weeks, Heres Why the Trend Might Reverse for Bluebird
Yahoo News
over three weeks ago at businesswire.com         
Acquisition by Vachon Mark of 49850 shares of Bluebird Bio at 0.44 subject to Rule 16b-3
businesswire News
over a year ago at finance.yahoo.com         
Antibody Drug Conjugates Global Market Report 2023
Yahoo News
over a week ago at news.google.com         
Collegium Pharmaceutical, Inc. Receives Average Recommendation of Moderate Buy from Brokerages - Mar...
Google News at Macroaxis
over a week ago at thelincolnianonline.com         
Empowered Funds LLC Acquires New Position in Collegium Pharmaceutical, Inc.
news
over two weeks ago at gurufocus.com         
Rubric Capital Management LP Adjusts Stake in Collegium Pharmaceutical Inc
Gurufocus Stories at Macroaxis
over two weeks ago at finance.yahoo.com         
Is Collegium Pharmaceutical a Great Value Stock Right Now?
Yahoo News
over two weeks ago at gurufocus.com         
Collegium Pharmaceutical Inc Stock Price Down 3.67 percent on Nov 12
Gurufocus Stories at Macroaxis
over three weeks ago at zacks.com         
Is the Options Market Predicting a Spike in Collegium Pharmaceutical Stock?
zacks News
over three weeks ago at finance.yahoo.com         
Collegium Pharmaceutical Inc Q3 2024 Earnings Call Highlights Record Revenue Growth and ...
Yahoo News
over three weeks ago at finance.yahoo.com         
Collegium Pharmaceutical Q3 Earnings Snapshot
Yahoo News
over three weeks ago at finance.yahoo.com         
Heres What Key Metrics Tell Us About Collegium Pharmaceutical Q3 Earnings
Yahoo News
over three weeks ago at gurufocus.com         
What To Expect From Collegium Pharmaceutical Inc Q3 2024 Earnings
Gurufocus Stories at Macroaxis
3 days ago at finance.yahoo.com         
Exploring High Growth Tech Stocks This November 2024
Yahoo News
few days ago at thelincolnianonline.com         
Yvonne Greenstreet Sells 5,219 Shares of Alnylam Pharmaceuticals, Inc. Stock
news
few days ago at investing.com         
Alnylam Pharmaceuticals CFO sells 422,144 in stock
Investing News at Macroaxis
few days ago at investing.com         
Alnylam shares retain Buy rating as analyst sees strong market for multiple ATTR-CM treatments
Investing News at Macroaxis
six days ago at investing.com         
Alnylam reiterates stock target, outperform rating post Attruby FDA nod
Investing News at Macroaxis
six days ago at finance.yahoo.com         
BridgeBio Soars After Drug Gets Nod in Rare Heart Condition
Yahoo News
over a week ago at finance.yahoo.com         
Paragon Therapeutics Appoints Susanna High as Chief Executive Officer
Yahoo News
over a week ago at thelincolnianonline.com         
Swiss National Bank Has 103.25 Million Stock Holdings in Alnylam Pharmaceuticals, Inc.
news
over a week ago at investing.com         
Alnylam stock holds price target and buy rating on promising drug data
Investing News at Macroaxis
over a week ago at investing.com         
Alnylam shares hold Buy rating as TD Cowen notes sustained efficacy in interim Phase 1b results
Investing News at Macroaxis
over a week ago at news.google.com         
StockNews.com Upgrades Voyager Therapeutics to Buy - MarketBeat
Google News at Macroaxis
over two weeks ago at investing.com         
Oppenheimer reiterates Voyager stock target, sees positive outlook from TOGETHER study
Investing News at Macroaxis
over three weeks ago at finance.yahoo.com         
Arcus Biosciences, Inc. Reports Q3 Loss, Tops Revenue Estimates
Yahoo News
over a month ago at news.google.com         
Voyager Therapeutics Expected to Beat Earnings Estimates Can the Stock Move Higher - Yahoo Finance
Google News at Macroaxis
over a month ago at simplywall.st         
Improved Revenues Required Before Voyager Therapeutics, Inc. Stocks 27 percent Jump Looks Justified
Simply Wall St News at Macroaxis
over a month ago at zacks.com         
GSKs NDA for UTI Drug Gepotidacin Gets FDAs Priority Review
zacks News
over a month ago at finance.yahoo.com         
Investing in Voyager Therapeutics three years ago would have delivered you a 58 percent gain
Yahoo News
over a month ago at simplywall.st         
Strong week for Voyager Therapeutics shareholders doesnt alleviate pain of five-year loss
Simply Wall St News at Macroaxis
over two months ago at news.google.com         
Voyager Therapeutics stock hits 52-week low at 5.95 - Investing.com
Google News at Macroaxis
over two months ago at finance.yahoo.com         
Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabl...
Yahoo News
few days ago at gurufocus.com         
Galapagos NV Stock Surges Amid Strong Industry Performance
Gurufocus Stories at Macroaxis
over two weeks ago at gurufocus.com         
Stonepine Capital Management, LLC Increases Stake in Verastem Inc
Gurufocus Stories at Macroaxis
over two weeks ago at gurufocus.com         
Prosight Management, LP Expands Stake in ADC Therapeutics SA
Gurufocus Stories at Macroaxis
over a month ago at insidermonkey.com         
Galapagos NV Q3 2024 Earnings Call Transcript
insidermonkey News
over a month ago at seekingalpha.com         
Galapagos reports 9M results
seekingalpha News
over three months ago at zacks.com         
Biotech Stock Roundup REGNs Drug Approval, LXRX, RYTM Stocks Gain on Update More
zacks News
over three months ago at zacks.com         
Galapagos Up on FDA Nod to Begin Phase III Lymphoma Study
zacks News
over three months ago at benzinga.com         
Galapagos receives transparency notification from FMR LLC
benzinga news
over three months ago at gurufocus.com         
Galapagos NV Earnings Call Transcript Highlights Strong Cash Position and ...
Gurufocus Stories at Macroaxis
over three months ago at benzinga.com         
FDA Approves Adaptimmune Therapeutics Engineered Cell Therapy As First For Solid Tumor And New Thera...
benzinga news
over a year ago at thelincolnianonline.com         
Ionis Pharmaceuticals Given New 34.00 Price Target at SVB Leerink
news
over a year ago at hawaiinewsnow.com         
Purchase by Sumitomo Chemical Co Ltd of 51599200 shares of Myovant Sciences
news
a minute ago at finance.yahoo.com         
Genethon Pursues Different Strategies for Ensuring Patient Access to Gene Therapies for Rare Disease...
Yahoo News
2 days ago at thelincolnianonline.com         
Fred Alger Management LLC Sells 31,373 Shares of Sarepta Therapeutics, Inc.
news
3 days ago at businesswire.com         
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635
businesswire News
few days ago at thelincolnianonline.com         
Qsemble Capital Management LP Makes New Investment in Sarepta Therapeutics, Inc.
news
few days ago at investing.com         
Sarepta stock rated Overweight after Arrowhead acquisition
Investing News at Macroaxis
few days ago at businesswire.com         
Insider Trading
businesswire News
few days ago at statnews.com         
Roches TIGIT troubles continue, a novel Alzheimers target misses the mark, and other biotech news
news
six days ago at thelincolnianonline.com         
Disposition of 11723 shares by Dallan Murray of Sarepta Therapeutics at 128.67 subject to Rule 16b-3
news
over a week ago at www.macroaxis.com         
Disposition of 11723 shares by Dallan Murray of Sarepta Therapeutics at 128.67 subject to Rule 16b-3
Macroaxis News
over a week ago at www.macroaxis.com         
Disposition of 11723 shares by Dallan Murray of Sarepta Therapeutics at 128.67 subject to Rule 16b-3
Macroaxis News
over a year ago at news.google.com         
In SOTU speech, Biden says hell veto IRA repeal efforts - FiercePharma
Google News at Macroaxis
over six months ago at thelincolnianonline.com         
Mirati Therapeutics Now Covered by Analysts at StockNews.com
news
over six months ago at finance.yahoo.com         
Billionaire Joe Lewis Pleads Guilty in Insider Trading Case
Yahoo News
over six months ago at smh.com.au         
Billionaire pleads guilty in insider trading case with a link to an Australian giant
news
over six months ago at streetinsider.com         
Frances Sanofi to buy U.S. drugs project INBRX-101 for about 2.2 billion
Street Insider News
over six months ago at streetinsider.com         
Frances Sanofi to buy U.S. drugs project INBRX-101 for about 2.2 billion
Street Insider News
over six months ago at streetinsider.com         
Frances Sanofi to buy U.S. drugs project INBRX-101 for about 2.2 billion
Street Insider News
over six months ago at streetinsider.com         
Frances Sanofi to buy U.S. drugs project INBRX-101 for about 2.2 billion
Street Insider News
over six months ago at aol.com         
Frances Sanofi to buy U.S. drugs project INBRX-101 for about 2.2 billion
news
over six months ago at seekingalpha.com         
Mirati Therapeutics stock ticks higher amid Nasdaq delisting for sale to Bristol-Myers
seekingalpha News
over six months ago at thelincolnianonline.com         
Brokerages Set Mirati Therapeutics, Inc. PT at 60.00
news
over a year ago at news.google.com         
Eylea Race Continues To Heat Up With Formycon Unveiling Early ... - Generics Bulletin
Google News at Macroaxis
a minute ago at finance.yahoo.com         
Neurocrines Phase II schizophrenia trial fails to meet primary endpoint
Yahoo News
few days ago at thelincolnianonline.com         
Truvestments Capital LLC Takes 63,000 Position in Neurocrine Biosciences, Inc.
news
over a week ago at thelincolnianonline.com         
Landscape Capital Management L.L.C. Invests 1 Million in Neurocrine Biosciences, Inc.
news
over a week ago at businesswire.com         
Helpr Employer-Subsidized Family Care App with Patented My Choice Technology Expands Service to 150 ...
businesswire News
over two weeks ago at thelincolnianonline.com         
Neurocrine Biosciences, Inc. Shares Bought by Impax Asset Management Group plc
news
over two weeks ago at investing.com         
Spruce Biosciences SWOT analysis tildacerfonts fate hangs on Q4 trial results
Investing News at Macroaxis
over two weeks ago at finance.yahoo.com         
Voyager Reports Third Quarter 2024 Financial and Operating Results
Yahoo News
over three weeks ago at finance.yahoo.com         
Disposition of 5140 shares by Roberts Eiry of Neurocrine Biosciences at 77.81 subject to Rule 16b-3
Yahoo News
over three weeks ago at finance.yahoo.com         
Neurocrine Biosciences Presents New Data on INGREZZA Capsules at Psych Congress 2024 Majority of Lon...
Yahoo News
over three weeks ago at thelincolnianonline.com         
Neurocrine Biosciences Issues Quarterly Earnings Results, Misses Expectations By 0.23 EPS
news
six days ago at gurufocus.com         
Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
Gurufocus Stories at Macroaxis
over two weeks ago at gurufocus.com         
Redmile Group, LLC Expands Stake in Nurix Therapeutics Inc
Gurufocus Stories at Macroaxis
over three weeks ago at gurufocus.com         
Morgan Stanleys Strategic Reduction in Nurix Therapeutics Holdings
Gurufocus Stories at Macroaxis
over three weeks ago at investing.com         
Disposition of 3290 shares by Christine Ring of Nurix Therapeutics at 25.0 subject to Rule 16b-3
Investing News at Macroaxis
over a month ago at investing.com         
Nurix therapeutics CFO Hans van Houte sells 86,083 in stock
Investing News at Macroaxis
over a month ago at investing.com         
Nurix therapeutics chief scientific officer sells shares worth 83,536
Investing News at Macroaxis
over a month ago at thelincolnianonline.com         
Insider Selling Nurix Therapeutics, Inc. Insider Sells 3,437 Shares of Stock
news
over a month ago at globenewswire.com         
Nurix Therapeutics Announces Presentations atthe 7th Annual TPD Induced Proximity Summit
Macroaxis News: globenewswire.com
over a month ago at finance.yahoo.com         
Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-...
Yahoo News
over a month ago at investing.com         
Nurix Therapeutics chief legal officer sells 82,250 in stock
Investing News at Macroaxis
over a year ago at news.google.com         
Global markets live Adobe, Eli Lilly, Nasdaq, Intel, UBS... - Marketscreener.com
Google News at Macroaxis
over a year ago at thelincolnianonline.com         
Boxer Capital LLC Boosts Stock Position in Prometheus Biosciences, Inc.
news
over a year ago at www.macroaxis.com         
Exercise or conversion by Mark McKenna of 122528 shares of Prometheus Biosciences subject to Rule 16...
Macroaxis News
over a year ago at news.google.com         
PROMETHEUS BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana Kahn Swick Foti, L...
Google News at Macroaxis
over a year ago at simplywall.st         
We Think Prometheus Biosciences Can Afford To Drive Business Growth
Simply Wall St News at Macroaxis
over a year ago at zacks.com         
Prometheus Biosciences, Inc. is a Great Momentum Stock Should You Buy?
zacks News
over a year ago at zacks.com         
Prometheus Biosciences, Inc. Reports Q1 Loss, Tops Revenue Estimates
zacks News
over a year ago at news.google.com         
Ieq Capital LLC Sells off 35.3 percent of Holding in Prometheus ... - Best Stocks
Google News at Macroaxis
over a year ago at news.google.com         
Cocrystal Pharma Appoints Pharma Industry Veteran Fred Hassan to its Board of Directors - Marketscre...
Google News at Macroaxis
over a year ago at fool.com         
Why Madrigal Pharmaceuticals Stock Gained 20 percent This Week
fool News
over six months ago at www.macroaxis.com         
Disposition of 8500 shares by Jonas Jeffrey M of Karuna Therapeutics at 128.01 subject to Rule 16b-3
Macroaxis News
over six months ago at bizjournals.com         
PureTechs newest biotech spinout represents a shift from the past
bizjournals News
over six months ago at news.google.com         
Disposition of 17350 shares by Stephen Brannan of Karuna Therapeutics at 187.26 subject to Rule 16b-...
Google News at Macroaxis
over six months ago at simplywall.st         
When Will Karuna Therapeutics, Inc. Turn A Profit?
Simply Wall St News at Macroaxis
over six months ago at news.google.com         
Karuna Therapeutics, Inc. Receives Consensus Recommendation of Hold from Analysts - Defense World
Google News at Macroaxis
over six months ago at finance.yahoo.com         
Bronte Amalthea Fund Incurred Loss in Karuna Therapeutics Short Position
Yahoo News
over six months ago at www.macroaxis.com         
Acquisition by Steven Paul of 47378 shares of Karuna Therapeutics at 315.18 subject to Rule 16b-3
Macroaxis News
over six months ago at seekingalpha.com         
Karuna Therapeutics stock drops on no apparent news amid deal with Bristol-Myers Squibb
seekingalpha News
over six months ago at thelincolnianonline.com         
Algert Global LLC Has 3.12 Million Stock Holdings in Karuna Therapeutics, Inc.
news
over six months ago at zacks.com         
Acquisition by Steven Paul of 27510 shares of Karuna Therapeutics at 7.27 subject to Rule 16b-3
zacks News
a day ago at thelincolnianonline.com         
Short Interest in Sutro Biopharma, Inc. Drops By 25.4
news
over a week ago at news.google.com         
Brokers Set Expectations for Sutro Biopharma FY2024 Earnings - MarketBeat
Google News at Macroaxis
over two weeks ago at gurufocus.com         
Sutro Biopharma Inc Q3 2024 Earnings Revenue Misses Estimates at 8. ...
Gurufocus Stories at Macroaxis
over three weeks ago at gurufocus.com         
Vanguard Group Incs Strategic Acquisition in Sutro Biopharma Inc
Gurufocus Stories at Macroaxis
over a month ago at news.google.com         
Sutro Biopharma shareholders have endured a 80 percent loss from investing in the stock three years ...
Google News at Macroaxis
over a month ago at www.macroaxis.com         
Acquisition by Gerber Hans-peter of 175000 shares of Sutro Biopharma at 3.77 subject to Rule 16b-3
Macroaxis News
over two months ago at www.macroaxis.com         
Disposition of 31125 shares by Newell William J of Sutro Biopharma subject to Rule 16b-3
Macroaxis News
over two months ago at www.macroaxis.com         
Disposition of 13380 shares by Gerber Hans-peter of Sutro Biopharma at 3.95 subject to Rule 16b-3
Macroaxis News
over two months ago at finance.yahoo.com         
Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pip...
Yahoo News
over three months ago at globenewswire.com         
Sutro Biopharma Announces Initiation of REFRME-L1 Phase 2 Trial with Luvelta for Patients with Non-S...
Macroaxis News: globenewswire.com
over a year ago at news.google.com         
FDA approves Regenerons Eylea for retinopathy of prematurity - FiercePharma
Google News at Macroaxis
few days ago at businesswire.com         
Xencor to Participate at Upcoming Investor Conferences
businesswire News
over a week ago at www.macroaxis.com         
Disposition of 13548 shares by Bassil Dahiyat of Xencor at 15.69 subject to Rule 16b-3
Macroaxis News
over a week ago at news.google.com         
Xencor, Inc. Receives Average Recommendation of Buy from Analysts - MarketBeat
Google News at Macroaxis
over two weeks ago at thelincolnianonline.com         
Xencor, Inc. CEO Bassil I. Dahiyat Sells 3,366 Shares
news
over two weeks ago at finance.yahoo.com         
Xencor s Technical Outlook is Bright After Key Golden Cross
Yahoo News
over two weeks ago at investing.com         
Xencor executive sells shares worth 1.6 million
Investing News at Macroaxis
over two weeks ago at www.macroaxis.com         
Disposition of 12774 shares by John Desjarlais of Xencor at 15.69 subject to Rule 16b-3
Macroaxis News
over three weeks ago at thelincolnianonline.com         
BMO Capital Markets Reaffirms Outperform Rating for Xencor
news
over three weeks ago at simplywall.st         
Xencor shareholders are up 7.9 percent this past week, but still in the red over the last three year...
Simply Wall St News at Macroaxis
over three weeks ago at investing.com         
Xencor Inc earnings beat by 0.27, revenue fell short of estimates
Investing News at Macroaxis
few days ago at investing.com         
Biomea Fusions SWOT analysis clinical hold impacts diabetes drug stock
Investing News at Macroaxis
over a week ago at thelincolnianonline.com         
Kura Oncology Earns Market Outperform Rating from JMP Securities
news
over a week ago at thelincolnianonline.com         
Kura Oncology Cut to Sell at StockNews.com
news
over a week ago at investing.com         
Kura Oncology stock gains momentum as Jefferies sees potential menin leadership
Investing News at Macroaxis
over a week ago at investors.com         
Kura Oncology Slams The Door On Its Takeover Narrative, And Shares Collapse 26
Investors Business Daily at Macroaxis
over a week ago at seekingalpha.com         
Analysts supportive of KuraKirin deal despite major selloff in shares
seekingalpha News
over a week ago at seekingalpha.com         
Kura stock slides 17 percent on Kyowa Kirin deal for ziftomenib
seekingalpha News
over two weeks ago at gurufocus.com         
Paradigm Biocapital Advisors LP Adjusts Stake in Kura Oncology Inc
Gurufocus Stories at Macroaxis
over three weeks ago at www.macroaxis.com         
Acquisition by Wilson Troy Edward of 300000 shares of Kura Oncology subject to Rule 16b-3
Macroaxis News
over three weeks ago at thelincolnianonline.com         
Kura Oncologys Outperform Rating Reiterated at Wedbush
news
over a year ago at news.google.com         
The Clock Is Ticking For Seres Therapeutics Im Not Afraid ... - Seeking Alpha
Google News at Macroaxis
over a week ago at news.google.com         
Allakos Reports Q3 2024 Results and Research Progress - TipRanks
Google News at Macroaxis
over two weeks ago at news.google.com         
FMR LLCs Strategic Acquisition of Allakos Inc Shares - GuruFocus.com
Google News at Macroaxis
over a month ago at simplywall.st         
Allakos Insiders Miss 24 percent Gain After Offloading Stock
Simply Wall St News at Macroaxis
over two months ago at thelincolnianonline.com         
JMP Securities Reaffirms Market Outperform Rating for Allakos
news
over two months ago at news.google.com         
Allakos stock plunges to 52-week low of 0.56 amid market challenges - Investing.com
Google News at Macroaxis
over two months ago at www.macroaxis.com         
Disposition of 13665 shares by Radford Harlan Baird of Allakos at 0.65 subject to Rule 16b-3
Macroaxis News
over three months ago at news.google.com         
Vanguard Group Inc. Raises Stock Holdings in Allakos Inc. - Defense World
Google News at Macroaxis
over three months ago at news.google.com         
Allakos stock plunges to 52-week low of 0.67 amid steep annual decline - Investing.com
Google News at Macroaxis
over three months ago at finance.yahoo.com         
Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results
Yahoo News
over three months ago at finance.yahoo.com         
Can Allakos Afford To Invest In Growth?
Yahoo News
six days ago at finance.yahoo.com         
Are Medical Stocks Lagging AnaptysBio This Year?
Yahoo News
over a week ago at investing.com         
Truist maintains hold on AnaptysBio with 30 target
Investing News at Macroaxis
over two weeks ago at thelincolnianonline.com         
AnaptysBio Price Target Lowered to 66.00 at JPMorgan Chase Co.
news
over three weeks ago at zacks.com         
Down -32.84 percent in 4 Weeks, Heres Why You Should You Buy the Dip in AnaptysBio
zacks News
over three weeks ago at finance.yahoo.com         
AnaptysBio Third Quarter 2024 Earnings Beats Expectations
Yahoo News
over three weeks ago at gurufocus.com         
AnaptysBio Inc Q3 2024 Earnings Revenue Soars to 30M, EPS Beats Estimates at -1.14
Gurufocus Stories at Macroaxis
over three weeks ago at investing.com         
AnaptysBio shares hold Outperform rating Leerink notes strong cash position and clinical progress
Investing News at Macroaxis
over three weeks ago at finance.yahoo.com         
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update
Yahoo News
over three weeks ago at zacks.com         
AnaptysBio, Inc. Reports Q3 Loss, Tops Revenue Estimates
zacks News
over a month ago at gurufocus.com         
AnaptysBio Shares Plunge as Eli Lilly Ends Arthritis Drug Research
Gurufocus Stories at Macroaxis
few days ago at thelincolnianonline.com         
Cynosure Group LLC Sells 499 Shares of argenx SE
news
over a week ago at investing.com         
Can Argenx stock sustain its autoimmune category dominance Oppenheimer weighs in
Investing News at Macroaxis
over a week ago at finance.yahoo.com         
Is argenx SE the Best Immunotherapy Stock to Buy Now?
Yahoo News
over two weeks ago at gurufocus.com         
Paradigm Biocapital Advisors LP Increases Stake in Tarsus Pharmaceuticals Inc
Gurufocus Stories at Macroaxis
over two weeks ago at gurufocus.com         
Deep Track Capital, LP Acquires New Stake in Silence Therapeutics PLC
Gurufocus Stories at Macroaxis
over two weeks ago at gurufocus.com         
Artisan Partners Limited Partnership Bolsters Stake in iRhythm Technologies Inc
Gurufocus Stories at Macroaxis
over three weeks ago at zacks.com         
Is Argenx Outperforming Other Medical Stocks This Year?
zacks News
over three weeks ago at thelincolnianonline.com         
argenx SE Stake Lowered by AlphaCentric Advisors LLC
news
over a month ago at thelincolnianonline.com         
argenx Issues Earnings Results
news
over a month ago at finance.yahoo.com         
Heres Why You Should Hold Argenx SE
Yahoo News
few days ago at finance.yahoo.com         
Health Canada approves Novo Nordisks Wegovy to cut heart attacks
Yahoo News
over a week ago at news.google.com         
Ascendis Pharmas SWOT analysis stock faces growth hurdles amid pipeline promise - Investing.com Indi...
Google News at Macroaxis
over two weeks ago at simplywall.st         
Ascendis Pharma Third Quarter 2024 Earnings Misses Expectations
Simply Wall St News at Macroaxis
over two weeks ago at investing.com         
Citi cuts Ascendis Pharma stock target, maintains buy rating on volume growth
Investing News at Macroaxis
over two weeks ago at insidermonkey.com         
Ascendis Pharma AS Q3 2024 Earnings Call Transcript
insidermonkey News
over two weeks ago at thelincolnianonline.com         
Sivik Global Healthcare LLC Buys Shares of 10,000 Ascendis Pharma AS
news
over two weeks ago at seekingalpha.com         
Ascendis Pharma GAAP EPS of -1.72, revenue of 57.83M
seekingalpha News
over two weeks ago at seekingalpha.com         
Ascendis Pharma Q3 2024 Earnings Preview
seekingalpha News
over three weeks ago at finance.yahoo.com         
Heres Why BioMarin Aristotle Large Cap Growth Strategy Divested From Pharmaceutical
Yahoo News
over three weeks ago at benzinga.com         
Novo Nordisk Q3 Preview Will 285 Million Weight Loss Bet Offset Bearish Charts?
benzinga news
over a year ago at news.google.com         
Taysha The FDA Just Stuck A Major Blow To Their Plans - Seeking Alpha
Google News at Macroaxis
six days ago at prnewswire.com         
Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Ob...
prnewswire News
six days ago at investing.com         
Biohaven shares retain Outperform rating as Baird highlights optimism for obesity Phase 2 trial
Investing News at Macroaxis
over a week ago at www.macroaxis.com         
Acquisition by John Childs of 16592 shares of Biohaven Pharmaceutical at 38.8 subject to Rule 16b-3
Macroaxis News
over two weeks ago at thelincolnianonline.com         
Biohaven Releases Earnings Results, Misses Estimates By 0.03 EPS
news
over two weeks ago at thelincolnianonline.com         
Biohaven Price Target Raised to 75.00
news
over three weeks ago at gurufocus.com         
Vanguard Group Incs Strategic Acquisition in Biohaven Ltd
Gurufocus Stories at Macroaxis
over a month ago at finance.yahoo.com         
He Made Pfizer a Household Name. Wall Street Wants More.
Yahoo News
over a month ago at finance.yahoo.com         
As a Billionaire Activist Takes a Stake, Is Now the Time to Buy Pfizer Stock?
Yahoo News
over a month ago at kalkinemedia.com         
Significant Insider Investments Highlight Confidence in Biohavens Growth
news
over a month ago at investing.com         
Biohaven director Childs buys shares worth nearly 1 million
Investing News at Macroaxis
a day ago at thelincolnianonline.com         
Edgestream Partners L.P. Has 5.19 Million Holdings in Blueprint Medicines Co.
news
3 days ago at thelincolnianonline.com         
2,998 Shares in Blueprint Medicines Co. Bought by Blueshift Asset Management LLC
news
over a week ago at investing.com         
Blueprint Medicines director Coats sells 1.87 million in stock
Investing News at Macroaxis
over a week ago at thelincolnianonline.com         
JMP Securities Reaffirms Market Outperform Rating for Blueprint Medicines
news
over two weeks ago at benzinga.com         
Blood Cancer-Focused Blueprint Medicines Could Be Attractive Target For Partnerships Analyst
benzinga news
over two weeks ago at www.macroaxis.com         
Disposition of 5000 shares by Albers Jeffrey W. of Blueprint Medicines at 102.0 subject to Rule 16b-...
Macroaxis News
over three weeks ago at investors.com         
Stocks Showing Improved Relative Strength Blueprint Medicines
Investors Business Daily at Macroaxis
over three weeks ago at finance.yahoo.com         
Analysts Have Made A Financial Statement On Blueprint Medicines Corporations Third-Quarter Report
Yahoo News
over a month ago at finance.yahoo.com         
Blueprint Medicines Third Quarter 2024 Earnings EPS Beats Expectations
Yahoo News
over a month ago at investing.com         
Earnings call Blueprint Medicines sees revenue soar with AYVAKIT sales
Investing News at Macroaxis
few days ago at gurufocus.com         
Celldex Therapeutics Stock Surges Amid Positive Institutional Ratings
Gurufocus Stories at Macroaxis
over a week ago at gurufocus.com         
Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a ...
Gurufocus Stories at Macroaxis
over a week ago at www.macroaxis.com         
Disposition of 10500 shares by Marino James J of Celldex Therapeutics subject to Rule 16b-3
Macroaxis News
over two weeks ago at gurufocus.com         
FMR LLCs Strategic Reduction in Celldex Therapeutics Inc Shares
Gurufocus Stories at Macroaxis
over two weeks ago at investing.com         
Celldex Therapeutics CEO Anthony Marucci buys 308,430 in stock
Investing News at Macroaxis
over two weeks ago at thelincolnianonline.com         
Celldex Therapeutics Buy Rating Reiterated at HC Wainwright
news
over three weeks ago at gurufocus.com         
Wellington Management Group LLPs Strategic Acquisition in Celldex Therapeutics Inc
Gurufocus Stories at Macroaxis
over three weeks ago at finance.yahoo.com         
Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Yahoo News
over three weeks ago at finance.yahoo.com         
Celldex Therapeutics Reports Q3 Loss, Tops Revenue Estimates
Yahoo News
over a month ago at finance.yahoo.com         
Celldex Therapeutics pulls back 6.1 percent this week, but still delivers shareholders fantastic 57 ...
Yahoo News
few days ago at www.macroaxis.com         
Acquisition by Ferrante Karen Jean of 2513 shares of Cogent Biosciences at 8.02 subject to Rule 16b-...
Macroaxis News
over two weeks ago at gurufocus.com         
COMMODORE CAPITAL LPs Strategic Acquisition in Cogent Biosciences Inc
Gurufocus Stories at Macroaxis
over two weeks ago at thelincolnianonline.com         
Cogent Biosciences Earns Neutral Rating from Wedbush
news
over two weeks ago at seekingalpha.com         
Cogent Biosciences GAAP EPS of -0.64 misses by 0.08
seekingalpha News
over three weeks ago at finance.yahoo.com         
Cogent Biosciences Announces Bezuclastinib Presentations at the 66th Annual American Society of Hema...
Yahoo News
over a month ago at thelincolnianonline.com         
Cogent Biosciences Stock Rating Reaffirmed by Needham Company LLC
news
over a month ago at finance.yahoo.com         
Analysts Rate Cogent Biosciences, Inc. as Moderate Buy with 15 Target
Yahoo News
over two months ago at thelincolnianonline.com         
Citigroup Increases Cogent Biosciences Price Target to 15.00
news
over two months ago at finance.yahoo.com         
Cogent Biosciences, Inc. This Small-Cap Healthcare Stock Is A Good Buy Right Now
Yahoo News
over three months ago at news.google.com         
Hennion Walsh Asset Management Inc. Invests 1.08 Million in Cogent Biosciences, Inc. - MarketBeat
Google News at Macroaxis
few days ago at benzinga.com         
Acquisition by Kevin Conroy of 102837 shares of EXACT Sciences at 13.96 subject to Rule 16b-3
benzinga news
few days ago at finance.yahoo.com         
Why Is Exact Sciences Stock Trading Higher On Monday?
Yahoo News
six days ago at finance.yahoo.com         
Exact Sciences Advances Breast Cancer Care with the Oncotype DX test and Genomic Profiling Research ...
Yahoo News
over a week ago at insidermonkey.com         
Exact Sciences Corporation Among the Best Genomics Stocks to Buy Right Now
insidermonkey News
over two weeks ago at simplywall.st         
Chairman of The Board CEO of Exact Sciences Picks Up 2.7 percent More Stock
Simply Wall St News at Macroaxis
over two weeks ago at gurufocus.com         
Capital World Investors Reduces Stake in Exact Sciences Corp
Gurufocus Stories at Macroaxis
over two weeks ago at gurufocus.com         
Exact Sciences Corp Stock Price Down 6.11 percent on Nov 12
Gurufocus Stories at Macroaxis
over two weeks ago at thelincolnianonline.com         
Exact Sciences Price Target Lowered to 60.00 at Evercore ISI
news
over three weeks ago at thelincolnianonline.com         
BTIG Research Has Lowered Expectations for Exact Sciences Stock Price
news
over three weeks ago at thelincolnianonline.com         
Stifel Nicolaus Has Lowered Expectations for Exact Sciences Stock Price
news
over a year ago at businesswire.com         
Verily Appoints Utpal Koppikar as Chief Financial Officer
businesswire News
over a week ago at news.google.com         
908 Devices earnings missed by 0.56, revenue fell short of estimates - Investing.com Nigeria
Google News at Macroaxis
over two weeks ago at finance.yahoo.com         
Analysts Have Lowered Expectations For 908 Devices Inc. After Its Latest Results
Yahoo News
over two weeks ago at bizjournals.com         
Boston firm to shift manufacturing to North Carolina
bizjournals News
over two weeks ago at insidermonkey.com         
908 Devices Inc. Q3 2024 Earnings Call Transcript
insidermonkey News
over two weeks ago at businesswire.com         
908 Devices Reports Third Quarter 2024 Financial Results and Updates 2024 Revenue Outlook
businesswire News
over two weeks ago at gurufocus.com         
What To Expect From 908 Devices Inc Q3 2024 Earnings
Gurufocus Stories at Macroaxis
over three weeks ago at simplywall.st         
US Penny Stocks 908 Devices Leads This Trio
Simply Wall St News at Macroaxis
over a month ago at www.macroaxis.com         
Acquisition by Hunt Anthony of 15996 shares of 908 Devices at 5.94 subject to Rule 16b-3
Macroaxis News
over a month ago at gurufocus.com         
908 Devices Inc Q2 2024 Earnings Call Highlights Strong Revenue Growth Amidst Challenges
Gurufocus Stories at Macroaxis
over two months ago at news.google.com         
908 Devices stock hits 52-week low at 3.44 amid market challenges - Investing.com
Google News at Macroaxis
a day ago at thelincolnianonline.com         
Erste Asset Management GmbH Takes Position in Vertex Pharmaceuticals Incorporated
news
3 days ago at zacks.com         
GILD vs. VRTX Which Stock Should Value Investors Buy Now?
zacks News
few days ago at fool.com         
Want 1 Million in Retirement 3 Stocks to Buy Now and Hold for Decades.
fool News
few days ago at thelincolnianonline.com         
Insider Selling Vertex, Inc. General Counsel Sells 3,020 Shares of Stock
news
few days ago at thelincolnianonline.com         
Douglass Winthrop Advisors LLC Reduces Stock Position in Vertex Pharmaceuticals Incorporated
news
few days ago at androidcentral.com         
Google adds premium tier to its Developer Program costing 299 per year
news
six days ago at kalkinemedia.com         
Long VRTX Vertex Pharmaceuticals Holds Major Support at 445 After Failed Breakout Above 500 Bullish ...
news
over a week ago at businesswire.com         
PwC erffnet Google Cloud AI Experience Zones mit Lsungen auf der Basis generativer KI von Google Clo...
businesswire News
over a week ago at thelincolnianonline.com         
Vertex Pharmaceuticals Incorporated Shares Purchased by Cerity Partners LLC
news
over a week ago at businesswire.com         
PwC ouvre des zones dexprience Google Cloud AI pour prsenter des solutions bases sur lIA gnrative de...
businesswire News
3 days ago at www.macroaxis.com         
Acquisition by Audhya Paul K. of 5000 shares of Kalvista Pharmaceuticals subject to Rule 16b-3
Macroaxis News
few days ago at simplywall.st         
Insiders At KalVista Pharmaceuticals Sold US2.5m Of Stock Potentially Indicating Weakness
Simply Wall St News at Macroaxis
few days ago at thelincolnianonline.com         
KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of DirectorsCambridge, Mass., Novem...
news
over a week ago at www.macroaxis.com         
Acquisition by Brian Piekos of 100000 shares of Kalvista Pharmaceuticals at 11.87 subject to Rule 16...
Macroaxis News
over two weeks ago at www.macroaxis.com         
Disposition of 12084 shares by Audhya Paul K. of Kalvista Pharmaceuticals subject to Rule 16b-3
Macroaxis News
over two weeks ago at gurufocus.com         
Capital World Investors Expands Stake in KalVista Pharmaceuticals
Gurufocus Stories at Macroaxis
over three weeks ago at businesswire.com         
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635
businesswire News
over three weeks ago at businesswire.com         
KalVista Pharmaceuticals Announces Pricing of a 55 Million Underwritten Offering of Common Stock and...
businesswire News
over a month ago at finance.yahoo.com         
KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asth...
Yahoo News
over a month ago at businesswire.com         
KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American Colle...
businesswire News
3 days ago at zacks.com         
Wall Street Analysts Think uniQure Could Surge 228.07 percent Read This Before Placing a Bet
zacks News
over a week ago at gurufocus.com         
uniQure Announces Dosing of First Patient in GenTLE Phase IIIa Clinical Trial of AMT-260 for ...
Gurufocus Stories at Macroaxis
over two weeks ago at news.google.com         
uniQure NV Enterprise Value -65.19 Mil - GuruFocus.com
Google News at Macroaxis
over three weeks ago at thelincolnianonline.com         
uniQure Releases Quarterly Earnings Results, Beats Expectations By 0.21 EPS
news
over three weeks ago at finance.yahoo.com         
uniQure Third Quarter 2024 Earnings EPS Beats Expectations, Revenues Lag
Yahoo News
over three weeks ago at gurufocus.com         
uniQure NV Q3 2024 Earnings EPS Loss of 0.91 Beats Estimates, Revenue of 2. ...
Gurufocus Stories at Macroaxis
over a month ago at zacks.com         
Amicus Therapeutics Reports Next Week Wall Street Expects Earnings Growth
zacks News
over a month ago at gurufocus.com         
State Street Corps Strategic Reduction in uniQure NV Holdings
Gurufocus Stories at Macroaxis
over a month ago at finance.yahoo.com         
uniQure Announces Dosing of First Patient in Phase III Clinical Trial of AMT-162 for the Treatment o...
Yahoo News
over two months ago at simplywall.st         
uniQure NASDAQQURE shareholders incur further losses as stock declines 10 percent this week, taking ...
Simply Wall St News at Macroaxis
2 days ago at thelincolnianonline.com         
Sage Therapeutics, Inc. Receives 12.83 Average PT from Analysts
news
few days ago at finance.yahoo.com         
A Brand New Bathhouse is Open in Renton
Yahoo News
over a week ago at seekingalpha.com         
Sage raised to sector perform by RBC in wake of drug failure
seekingalpha News
over a week ago at businesswire.com         
Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor in the T...
businesswire News
over a week ago at bizjournals.com         
Third trial failure is end-of-the-road for Sages neurological drug
bizjournals News
over two weeks ago at accesswire.com         
SOHM, Inc. Announces Allowances Of Japanese Patent Claims Received from Japans Patent Office Protect...
news
over three weeks ago at finance.yahoo.com         
Acumen Pharmaceuticals Appoints Dr. Amy Schacterle as Chief Regulatory Officer Head of Quality
Yahoo News
over a month ago at thelincolnianonline.com         
Sage Therapeutics Price Target Cut to 8.00 by Analysts at Oppenheimer
news
over a month ago at bizjournals.com         
Cambridge biotechs layoffs will cut dozens of Mass. employees
bizjournals News
over a month ago at globenewswire.com         
Sage and Artis Trade Join Forces to Accelerate Document Automation and Drive Efficiency in Secured F...
Macroaxis News: globenewswire.com
Far too much social signal, news, headlines, and media speculation about Eventide Healthcare that are available to investors today. That information is available publicly through Eventide media outlets and privately through word of mouth or via Eventide internal channels. However, regardless of the origin, that massive amount of Eventide data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Eventide Healthcare news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Eventide Healthcare relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Eventide Healthcare's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Eventide Healthcare alpha.

Other Information on Investing in Eventide Mutual Fund

Eventide Healthcare financial ratios help investors to determine whether Eventide Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Eventide with respect to the benefits of owning Eventide Healthcare security.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume